Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
2 suscriptores
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Página
1.262 / 1.539
#10089

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Mas de lo mismo,thld es el dia de la marmota,no he visto nunca nada igual. Que accion mas puerca,tiene menos fuerza que un muelle de cuerda.

#10090

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

En el tablon de Yahoo colgaron esto hace 1 hora:

Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.

Background: Tumors often consist of highly hypoxic subregions known to be resistant to chemotherapy and radiotherapy. TH-302 is an investigational hypoxia-targeted drug with a 2-nitroimidazole trigger designed to release the DNA alkylator bromo-isophosphoramide mustard (Br-IPM) when reduced in severe hypoxia. Preclinical models demonstrate that treatment with sunitinib increased the tumor hypoxic fraction, the therapeutic target of TH-302. Initiating TH-302 following sunitinib significantly increased the efficacy of sunitinib in these models. In this phase 1 dose escalation study, TH-302 was combined with standard dose sunitinib. Methods: Eligible patients (pts) for the study (NCT01381822) had advanced RCC, GIST or PNET tumors, evaluable disease by RECIST, ECOG ≤2 and acceptable hematologic, hepatic and renal function. Pts received TH-302 in combination with standard full doses of 50 mg PO sunitinib daily from Day 1 to Day 28 of a 6 week cycle. TH-302 was administered IV on Days 8, 15 and 22. TH-302 starting dose was 240 mg/m2. The study objectives were to determine the MTD, DLTs and RP2D and to evaluate the safety and preliminary efficacy of TH-302 when used in combination with sunitinib. Results: Ten pts were enrolled. Median age: 63 (range 27-72); Female (5)/ Male (5); ECOG 0 (5); ECOG 1 (5); Primary tumor: RCC (6), GIST (4). Median prior chemotherapies: 3 (range: 0-3) including prior sunitinib in 7 pts. No DLTs were observed in the 3 pts at the 240 mg/m2 cohort and 1 pt of 5 DLT evaluable in the 340 mg/m2 cohort had a DLT of stomatitis. Eight pts discontinued (progressive disease (6), pursued other treatment options, adverse event unrelated to study drugs). Three pts had a study drug related SAE (neutropenic sepsis, anemia, hyperthyroidism). Common TH-302 related AEs were nausea and mucosal toxicity and were mostly grade 1 or 2. Grade 3/4 thrombocytopenia and neutropenia were reported in 4 pts and 3 pts, respectively. One of 4 (25%) pts with GIST had a confirmed PR and 3 of 4 (75%) pts with RCC had PRs including 2 with confirmed PRs. Conclusions: TH-302 can be administered in combination with full dose sunitinib. Mucositis was dose limiting. There is preliminary evidence of activity of TH-302 in combination with sunitinib in RCC. Clinical trial information: NCT01381822. Less

#10091

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

5,32...llegando al siguiente soporte!
Tocando ya el soporte de 5,30...ojito a ver que pasa.

#10093

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Yo es que tengo ya un cacao de noticias,fechas,soportes y resistencias que voy a necesitar un lapiz y papel para no liarme.
Gracias por la aclaracion

#10095

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

lápiz y papel, ahora hay unos aparatejos con una fruta detrás, ande vassssssss.

#10096

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Framus, me gustaria saber tu opinion sobre algo que se me pasa por la cabeza cada vez que hay una conference de este tipo. O son muy muy muy malos haciendo 'presentaciones,lo cual por si mismo es patetico o es que ellos mismos saben que tienen una especie de bufo farmaceutico,es decir,que es como un sufle que ha crecido todo lo que ha podido,pero que cuando alguien abra el horno y le clave el cuchillo para ver que hay dentro se va a encontrar aire.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Nvidia bate expectativas pero decepciona. Insiders reafirman su posición